+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 314 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5916010
The worldwide market for dry eye syndrome treatment is experiencing robust growth, culminating in a total revenue of US$ 5.4 billion in 2024. Projections indicate that by the end of 2031, the market is poised to achieve a substantial valuation of US$ 9 billion.

Strategies to Propel Growth for Dry Eye Syndrome Treatment Manufacturers

Increasing LASIK Surgeries, Expanding R&D Initiatives, and a Surge in Drug Candidates Fuel Business Growth

The dry eye disease market has witnessed notable trends, including a surge in research and development investments, successful clinical trials, and a rising number of new product approvals. Numerous stakeholders are actively engaged in clinical research, exemplified by Reproxalap, a pipeline candidate by Aldeyra Therapeutics, Inc., currently in Phase III trials. Such endeavors hold significant potential to drive revenue within the dry eye syndrome treatment market.

Dry eye syndrome often emerges as a significant side effect following LASIK surgery, prompting prominent manufacturers to focus on developing supplements tailored for post-LASIK dry eye patients. Consequently, the growing number of LASIK surgeries emerges as a key driver fueling market expansion. For instance, data from the American Refractive Surgery Council reveals that more than 30% of patients undergoing eye surgery are likely to develop dry eye syndrome within the first three months.

Factors Constraining Global Sales of Dry Eye Syndrome Treatment

Limited Awareness Hampers Market Expansion

A notable challenge restraining market growth is the lack of public awareness regarding eye health. Many symptoms of dry eye, which can be effectively treated or alleviated with proper diagnosis and medications, remain poorly understood. Patients often fail to seek consultation with ophthalmologists until they encounter severe clinical issues. Consequently, symptoms like redness, inflammation, and other indicators of dry eye are frequently overlooked and misdiagnosed, leading to fewer patients receiving prescription medications.

Impact of COVID-19 on the Global Dry Eye Syndrome Treatment Market

Revenue Impacted by Reduced Sales of Dry Eye Drugs Due to COVID-19

The COVID-19 pandemic had an adverse effect on the sales of dry eye medications. Lockdowns and other restrictions implemented in affected regions to curb the virus's spread led to a significant decline in sales for manufacturers of dry eye medications. For instance, Novartis AG reported a 31.4% drop in sales of its Xiidra dry eye medication, from US$ 104.0 million in the second quarter of 2019 to US$ 79 million in the second quarter of 2020. Additionally, the pandemic substantially reduced the frequency of new eye exams in affected nations, resulting in decreased demand for dry eye medications.

Country-Wise Insights

  • U.S. Market Growth: The United States exhibits a robust dry eye syndrome treatment market, driven by a large target population, improved healthcare access, and high treatment adoption rates. The region's market profitability attracts companies, with innovative awareness campaigns further educating the public about early eye treatments.
  • U.K. Market Opportunity: High investments in research and development aimed at developing effective treatment options foster growth in the U.K.'s dry eye syndrome treatment market. An aging population and increasing LASIK surgeries contribute to market expansion.
  • Indian Market Attractiveness: India, with its substantial population and cost-effective labor, emerges as an attractive market for dry eye disease treatments. Leading competitors have established production facilities in India, with rising healthcare spending and expanding infrastructure fueling growth.
  • Chinese Demand Outlook: China's pharmaceutical industry comprises mainly small and medium-sized businesses with limited R&D expenditures. However, pharmaceutical multinationals like AstraZeneca, Novartis, and Novo Nordisk hold significant market shares. Government initiatives aim to consolidate the pharmaceutical industry, which may impact the dry eye syndrome treatment market.
These dynamics offer new opportunities for product launches and market expansion, setting the stage for substantial growth.

Competitive Landscape

Key companies in the dry eye syndrome treatment market are focusing on expanding their product portfolios through ongoing research and development and product launches. They are forming strategic partnerships with mid-sized or smaller players and expanding production facilities to strengthen their market presence and expand their dry eye syndrome treatment product lines. This strategy is anticipated to enhance their sales footprint in the global dry eye syndrome treatment industry.

Key Companies Profiled:

  • Allergan Plc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Bausch Health Companies Inc
  • Akorn, Inc.
  • Johnson & Johnson Inc.
  • Thea Pharmaceutical Limited
  • OASIS Medical
  • Altair Pharmaceutical Inc.
  • Boiron USA
  • Similasan Corporation
  • Scope Ophthalmic Ltd.
  • Reckitt Benkiser Group Plc.
  • Medicom Healthcare Ltd.
  • FDC Limited
  • Jamjom Pharmaceutical Co.
  • Lupin Limited
  • Sentis Pharma Private Limited

Key Segments Covered in Dry Eye Syndrome Treatment Industry Research

By Product:

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Removable
  • Dissolvable
  • Omega Supplements
  • Others

By Prescription Type:

  • Rx
  • OTC
  • Medical Devices

By Distribution Channel:

  • Hospital Pharmacies
  • Eye Health Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Dry Eye Syndrome Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
3.1. Global Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Cyclosporine
3.1.1.2. Topical Corticosteroids
3.1.1.3. Artificial Tears
3.1.1.4. Punctal Plugs
3.1.1.5. Omega Supplements
3.1.1.6. Others
3.2. Global Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Rx
3.2.1.2. OTC
3.2.1.3. Medical Devices
3.3. Global Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Eye Health Clinics
3.3.1.3. Retail Pharmacies
3.3.1.4. Online Pharmacies
3.4. Global Dry Eye Syndrome Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
4.1. North America Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Cyclosporine
4.1.1.2. Topical Corticosteroids
4.1.1.3. Artificial Tears
4.1.1.4. Punctal Plugs
4.1.1.5. Omega Supplements
4.1.1.6. Others
4.2. North America Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Rx
4.2.1.2. OTC
4.2.1.3. Medical Devices
4.3. North America Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Eye Health Clinics
4.3.1.3. Retail Pharmacies
4.3.1.4. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
5.1. Europe Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Cyclosporine
5.1.1.2. Topical Corticosteroids
5.1.1.3. Artificial Tears
5.1.1.4. Punctal Plugs
5.1.1.5. Omega Supplements
5.1.1.6. Others
5.2. Europe Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Rx
5.2.1.2. OTC
5.2.1.3. Medical Devices
5.3. Europe Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Eye Health Clinics
5.3.1.3. Retail Pharmacies
5.3.1.4. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Cyclosporine
6.1.1.2. Topical Corticosteroids
6.1.1.3. Artificial Tears
6.1.1.4. Punctal Plugs
6.1.1.5. Omega Supplements
6.1.1.6. Others
6.2. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Rx
6.2.1.2. OTC
6.2.1.3. Medical Devices
6.3. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Eye Health Clinics
6.3.1.3. Retail Pharmacies
6.3.1.4. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
7.1. Latin America Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Cyclosporine
7.1.1.2. Topical Corticosteroids
7.1.1.3. Artificial Tears
7.1.1.4. Punctal Plugs
7.1.1.5. Omega Supplements
7.1.1.6. Others
7.2. Latin America Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
7.2.1.1. Rx
7.2.1.2. OTC
7.2.1.3. Medical Devices
7.3. Latin America Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Eye Health Clinics
7.3.1.3. Retail Pharmacies
7.3.1.4. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Cyclosporine
8.1.1.2. Topical Corticosteroids
8.1.1.3. Artificial Tears
8.1.1.4. Punctal Plugs
8.1.1.5. Omega Supplements
8.1.1.6. Others
8.2. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Rx
8.2.1.2. OTC
8.2.1.3. Medical Devices
8.3. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Eye Health Clinics
8.3.1.3. Retail Pharmacies
8.3.1.4. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Prescription Type Heat map
9.2. Manufacturer vs by Prescription Type Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Allergan Plc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Novartis AG
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Otsuka Pharmaceutical Co. Ltd.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Santen Pharmaceutical Co. Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Bausch Health Companies Inc
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Akorn, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Johnson & Johnson Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Thea Pharmaceutical Limited
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. OASIS Medical
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Altair Pharmaceutical Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Boiron USA
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Similasan Corporation
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan Plc.
  • Novartis AG
  • Otsuka Pharmaceutical Co.,Ltd.
  • Santen Pharmaceutical Co Ltd.
  • Bausch Health Companies Inc.
  • Akorn, Inc.
  • Johnson & Johnson, Inc.
  • Thea Pharmaceuticals Limited
  • OASIS Medical
  • Altaire Pharmaceuticals Inc.
  • Boiron USA
  • Similasan Corporation
  • Scope Ophthalmics Ltd.
  • Reckitt Benckiser Group PLC
  • Medicom Healthcare Ltd
  • FDC Limited.
  • Lupin Limited
  • Jamjoom Pharmaceuticals Co.
  • Sentiss Pharma Private limited

Methodology

Loading
LOADING...